由于美国的竞争、定价和重组成本, Novo Nordisk削减了2025年预测。 Novo Nordisk cut 2025 forecasts due to U.S. competition, pricing, and restructuring costs.

Novo Nordisk降低了对2025年销售和营业利润的增长预测,理由是竞争加剧、定价压力以及美国广泛使用低成本的Ozempic和Wegovy复合版本。 Novo Nordisk has lowered its 2025 growth forecasts for sales and operating profit, citing increased competition, pricing pressures, and widespread use of lower-cost compounding versions of Ozempic and Wegovy in the U.S. 尽管这两种药物的销售增长强劲,但该公司现在预计销售增长8%至11%,利润增长4%至7%,低于以前的目标。 Despite strong sales growth for both drugs, the company now expects sales growth of 8% to 11% and profit growth of 4% to 7%, down from prior targets. 净利润下降了27%,达到200亿丹麦克朗,因为90亿丹麦克朗的结构调整费用与9 000个工作岗位的削减挂钩。 Net profit fell 27% to 20 billion Danish kroner due to 9 billion kroner in restructuring costs tied to a 9,000-job reduction. 首席执行官迈克·杜斯特达尔 （Mike Doustdar） 领导了一项重大转型，包括辉瑞公司在法庭上对 Metsera 的 100 亿美元收购。 CEO Mike Doustdar leads a major transformation, including a $10 billion bid for Metsera that Pfizer is challenging in court. 在美国努力降低药品价格的同时,该公司还在扩大直接到病人的就诊服务。 The company is also expanding direct-to-patient access amid U.S. efforts to lower drug prices.